Blinatumomab | Interleukin Related interleukin-related.com

Product Name :
Blinatumomab

Search keywords :
Blinatumomab

drugId :
null

Target Vo:
B-lymphocyte antigen CD19

Target Vo Short Name :
CD19

Moa_Name:
CD3 T-cell engagers

First Approval Country :
United States

First Approval Date Filter:
2014

Origin Company_Name :
Micromet Inc

Active Company_Name :
Amgen Europe Bv

Active Indication_Name:
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

In Active Indication_Name:
Multiple Myeloma

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Approved

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
iNOS Antibody
HIF1 alpha Antibody
CD44 Antibody: CD44 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 82 kDa, targeting to CD44. It can be used for WB,IHC-P,FC assays with tag free, in the background of Human, Mouse.

Author: Interleukin Related

Related Posts